Last reviewed · How we verify
NCT06939556: DEVHISE
High-throughput Serological Testing of Antibodies Platform
trial in Diagnostics in 152 participants. Currently enrolling.
30 July 2025
Quick facts
| Lead sponsor | Istituto Zooprofilattico Sperimentale delle Venezie |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 152 |
| Start date | 15 April 2025 |
| Primary completion | 30 July 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 2 locations across Italy |
Conditions studied
- Diagnostics — all drugs for Diagnostics →
- Pandemic Response — all drugs for Pandemic Response →
Sponsor
Istituto Zooprofilattico Sperimentale delle Venezie
Who can join
Adults 2 to 65, any sex, with Diagnostics or Pandemic Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the case of large emergency serosurveys, innovation in the sampling techniques is an often neglected, but relevant aspect to facilitate the enrolment of subjects in both adult and paediatric populations. Further, neutralization assays are the first line of response immediately after the emergence of a novel virus in the human population. This study aims at developing at IZSVe 384-format high-throughput neutralization assays for emerging and re-emerging respiratory viruses with pandemic potential to increase the preparedness capacity at both regional and national levels. This diagnostic platform will include the validation of Mitra VAMS devices for gathering blood samples for the diagnostic procedure. The platform will be tested and validated using adult subject-matched serum samples collected by venipuncture and finger-prick with volumetric tip microsampling devices (Mitra VAMS). This comparison will focus on the titration of antibodies against endemic viruses like influenza type A (i.e., seasonal influenza strains, like pdmH1N1 or H3N2) and SARS-CoV-2. The same serological assay will be developed to titrate neutralizing antibodies against emerging pathogens like avian influenza viruses of the H3 and H5 subtypes, Zika virus, and MERS-CoV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06939556
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diagnostics
Currently open trials in the same condition.
- NCT05989802 — Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children · NA · recruiting
- NCT04396925 — Point-of-care Ultrasonography in Norwegian General Practice · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06939556 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Zooprofilattico Sperimentale delle Venezie
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06939556.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing